Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Director Sells $50,812.50 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Director Kathy Hibbs sold 6,250 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $8.13, for a total value of $50,812.50. Following the completion of the sale, the director owned 96,992 shares of the company’s stock, valued at $788,544.96. This trade represents a 6.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Trading Up 3.4%

NASDAQ:SOPH opened at $7.87 on Friday. SOPHiA GENETICS SA has a fifty-two week low of $3.10 and a fifty-two week high of $8.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The stock has a market capitalization of $660.21 million, a PE ratio of -6.84 and a beta of 0.98. The business’s 50-day simple moving average is $7.03 and its 200-day simple moving average is $5.68.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Sell-side analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on SOPH shares. BTIG Research increased their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. HC Wainwright boosted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

Hedge Funds Weigh In On SOPHiA GENETICS

Large investors have recently bought and sold shares of the company. Perkins Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the 4th quarter worth approximately $49,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the third quarter worth $49,000. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS in the first quarter worth $50,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS during the fourth quarter worth $54,000. Finally, XTX Topco Ltd bought a new position in SOPHiA GENETICS in the fourth quarter valued at $55,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.